0.5 CME Credits. This webinar is a 30-minute overview of psychological and psychodynamic factors that can impact the psychopharmacological treatment of patients.

0.5 CME Credits. This webinar is a comprehensive 30-minute overview of psychodynamic principles, processes, and evolution for mental health professionals.

0.75 CME Credits. This webinar discusses ADHD and its varied presentations, co-occurring issues, and the importance of accurate assessment for effective treatment.

0.50 CME Credits. Dr. Collier explores diagnosis, overlapping symptoms, and treatments for delirium in older adults.

0.25 CME Credits. In this episode, we explore nine groundbreaking stories in mental health and psychiatric medicine, covering everything from healthcare fraud to the latest advancements in drug trials. First, we dive into the recent charges brought by the US Department of Justice against executives at Done, a California-based telehealth company, for alleged healthcare fraud. Done is accused of prescribing over 40 million Adderall pills to patients without proper evaluation, raising concerns about the balance between increasing mental healthcare access and responsible prescribing practices.

Pramipexole has moved up the in our algorithm for treatment resistant depression. Today, learn how to use this dopamine agonist.

New research moves pramipexole up in the algorithm for treatment resistant depression.

We interview Steve Hayes, originator of Acceptance and Commitment Therapy, on the personal struggles that inspired the treatment.

An interview with Steve Hayes, originator of Acceptance and Commitment Therapy (ACT), on how his struggle with panic disorder inspired his work.

A parent sits across from you and asks, "Why can't my child just take the same anxiety medicine that helps me?” Sounds reasonable, but the evidence tells a very different story.

Depression distorts memory. Measurement restores it. 

In December 2025, Flow did in fact receive FDA Approval, based on data from the Empower trial. Before that, it had been marketed under FDA clearance—a lower evidentiary bar. That correction matters—and it sharpens the question many subscribers have been asking me: How much does FDA approval tell us about real‑world effectiveness?

Psychodynamic therapy isn’t outdated.
It’s evolving. Grounded in evidence.

You’ve just given a preliminary diagnosis of borderline personality disorder. Now what?